^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS mutation

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) (NCT07472478)
    Phase 2
    Guangdong Provincial People's Hospital
    Not yet recruiting
    Last update posted :
    03/16/2026
    Initiation :
    03/15/2026
    Primary completion :
    12/31/2027
    Completion :
    03/31/2028
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    carboplatin • paclitaxel • Anfangning (garsorasib) • Idafang (ivonescimab)
    T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor (NCT07474168)
    Phase 1
    Zhejiang University
    Active, not recruiting
    Last update posted :
    03/16/2026
    Initiation :
    12/15/2025
    Primary completion :
    02/01/2027
    Completion :
    02/01/2032
    KRAS
    |
    KRAS mutation • KRAS G12
    Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) (NCT05853575)
    Phase 2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/16/2024
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596)
    Phase 2/3
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/02/2020
    Primary completion :
    10/31/2028
    Completion :
    10/31/2029
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/14/2014
    Primary completion :
    08/25/2021
    Completion :
    01/25/2026
    HER-2 • KRAS • BRAF • NRAS • HRAS • EGF
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) (NCT05132075)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/23/2022
    Primary completion :
    10/01/2025
    Completion :
    10/31/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    docetaxel • opnurasib (JDQ443)
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations (NCT06043713)
    Phase 1
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/15/2023
    Primary completion :
    12/31/2025
    Completion :
    02/09/2026
    HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) (KRYSTAL-2) (NCT04330664)
    Phase 1
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/07/2020
    Primary completion :
    07/29/2022
    Completion :
    02/24/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • batoprotafib (TNO155)
    A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1) (NCT04302025)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/06/2020
    Primary completion :
    12/30/2025
    Completion :
    03/06/2029
    PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)
    A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway (NCT05578092)
    Phase 1/2
    Mirati Therapeutics Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/02/2022
    Primary completion :
    06/30/2026
    Completion :
    07/30/2026
    EGFR • KRAS • NF1 • PTPN11
    |
    KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • MRTX0902
    Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (NCT05554367)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/13/2023
    Primary completion :
    08/26/2026
    Completion :
    08/26/2026
    KRAS • BRAF • NRAS • HRAS • RAS
    |
    BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12
    |
    Ibrance (palbociclib) • Mektovi (binimetinib)
    Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor (AFNT211-22-101) (NCT06105021)
    Phase 1/2
    Affini-T Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/06/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2029
    KRAS
    |
    KRAS mutation • KRAS G12
    |
    AFNT-211